Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Extrinsic and Intrinsic Pathways of Hemostasis01:20

Extrinsic and Intrinsic Pathways of Hemostasis

14.3K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
14.3K
Formation of the Platelet Plug01:22

Formation of the Platelet Plug

10.2K
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
10.2K
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

2.2K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.2K
Coagulation01:09

Coagulation

11.4K
The coagulation phase is a critical part of the body's process to prevent blood loss following injury to blood vessels. It involves chemical reactions that form a clot to seal the injured area. The clotting process begins shortly after injury, within 15-20 seconds for severe damage and 1-2 minutes for minor injuries.
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
11.4K
Clot Retraction and Fibrinolysis01:16

Clot Retraction and Fibrinolysis

9.7K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
9.7K
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

2.6K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A human pan-disease blood atlas of the circulating proteome.

Science (New York, N.Y.)·2025
Same author

A multiomics approach reveals novel regulators of plasma factor V levels, highlighting CLEC4M as a clearance receptor.

Blood·2025
Same author

Epidemiology, Treatment Patterns, and Cost Analysis of Immune Thrombocytopenia in Spain between 2014 and 2020: A Population-based Study.

TH open : companion journal to thrombosis and haemostasis·2024
Same author

Author Correction: Elevated plasma complement factor H related 5 protein is associated with venous thromboembolism.

Nature communications·2023
Same author

Characteristics of patients with chronic hypoparathyroidism not adequately controlled with conventional treatment and management patterns in Spain.

Endocrinologia, diabetes y nutricion·2021
Same author

Identification of the factor XII contact activation site enables sensitive coagulation diagnostics.

Nature communications·2021

Related Experiment Video

Updated: Mar 5, 2026

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
13:08

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Published on: September 9, 2012

19.5K

Factor XII Contact Activation.

Clément Naudin1,2, Elena Burillo1,2, Stefan Blankenberg3

  • 1Clinical Chemistry, Department of Molecular Medicine and Surgery, Karolinska Institutet and University Hospital, Stockholm, Sweden.

Seminars in Thrombosis and Hemostasis
|March 28, 2017
PubMed
Summary

Contact activation transforms factor XII (FXII) into FXIIa upon surface binding. This process is crucial for inflammation and blood clotting, with implications for diseases like hereditary angioedema.

More Related Videos

A Microfluidic Flow Chamber Model for Platelet Transfusion and Hemostasis Measures Platelet Deposition and Fibrin Formation in Real-time
09:38

A Microfluidic Flow Chamber Model for Platelet Transfusion and Hemostasis Measures Platelet Deposition and Fibrin Formation in Real-time

Published on: February 14, 2017

14.5K
Author Spotlight: High-Sensitivity Tissue Factor Activity Assay for Plasma Diagnosis
03:53

Author Spotlight: High-Sensitivity Tissue Factor Activity Assay for Plasma Diagnosis

Published on: December 29, 2023

1.3K

Related Experiment Videos

Last Updated: Mar 5, 2026

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
13:08

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Published on: September 9, 2012

19.5K
A Microfluidic Flow Chamber Model for Platelet Transfusion and Hemostasis Measures Platelet Deposition and Fibrin Formation in Real-time
09:38

A Microfluidic Flow Chamber Model for Platelet Transfusion and Hemostasis Measures Platelet Deposition and Fibrin Formation in Real-time

Published on: February 14, 2017

14.5K
Author Spotlight: High-Sensitivity Tissue Factor Activity Assay for Plasma Diagnosis
03:53

Author Spotlight: High-Sensitivity Tissue Factor Activity Assay for Plasma Diagnosis

Published on: December 29, 2023

1.3K

Area of Science:

  • Biochemistry
  • Hematology
  • Immunology

Background:

  • Contact activation involves the surface-induced conversion of factor XII (FXII) zymogen to the serine protease FXIIa.
  • FXII zymogen autoactivates upon binding to negatively charged surfaces like misfolded proteins, collagen, nucleic acids, and polyphosphates.
  • Activated FXII initiates the kallikrein-kinin system and intrinsic coagulation pathway, producing bradykinin and thrombin.

Purpose of the Study:

  • To review the molecular mechanisms of FXII contact activation.
  • To discuss the role of FXII contact activation in pathological thrombosis and disease states.
  • To provide an overview of FXII contact activation-associated diseases.

Main Methods:

  • Literature review of FXII contact activation.
  • Analysis of molecular interactions and pathways.
  • Examination of clinical implications and disease associations.

Main Results:

  • FXII contact activation is initiated by various negatively charged surfaces.
  • Activated FXII (FXIIa) plays a dual role in inflammation and coagulation.
  • Dysregulation of FXII contact activation is linked to thrombotic disorders and hereditary angioedema type III.

Conclusions:

  • FXII contact activation is a critical process with significant implications for human health.
  • Understanding FXII contact activation is essential for developing treatments for related diseases.
  • Further research into FXII pathways may reveal new therapeutic targets.